Aromatase inhibitors (AIs) have emerged as the standard therapy for postmenopausal patients with estrogen/progesterone receptor-positive breast cancer. As adjuvant therapy, treatment is typically ...

Aromatase Inhibitors and the Syndrome of Arthralgias With Estrogen Deprivation Arthritis & Rheumatism. 2005;52 (9):2594-2598. 0 ...

KISQALI is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

MONTREAL, June 18, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI ® (ribociclib tablets) in combination with an aromatase ...

Aromatase is a well-established target for the chemoprevention of breast cancer. The dihydroisocoumarin (3R,4R)-(−)-6-methoxy-1-oxo-3-pentyl-3,4-dihydro-1H-isochromen-4-yl acetate (1) (IC50 = 1.6 ± ...

Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis K Boszkiewicz and others Journal of Clinical Medicine, ...

Following our SAR studies on aromatase inhibitors, new compounds were designed by appropriately modifying the structure of flavone 1 using our previously reported CoMFA model. While the introduction ...